For research use only. Not for therapeutic Use.
| Catalog Number | R067974 |
| Synonyms | N-C16:0-Ceramide trihexoside; N-Hexadecanoyl globotriaosylceramide |
| Molecular Formula | C52H97NO18 |
| Purity | ≥95% |
| Solubility | DMSO, hot methanol, chloroform/methanol, 2:1 |
| Storage | Store at -20°C |
| Reference | <br>1. M. Fuller et al. “Urinary Lipid Profiling for the Identification of Fabry Hemizygotes and Heterozygotes” Clinical Chemistry, Vol. 51 pp. 688-694, 2005<br>2. S. Ashkenazi and T. G. Cleary, “Rapid method to detect shiga toxin and shiga-like toxin I based on binding to globotriosyl ceramide (Gb3), their naturalreceptor.” J Clin Microbio. June; 27(6): 1145-1150, 1989<br>3. S. Bekri, O. Lidove, R. Jaussaud, B. Knebelmann, F. Barbey. /The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up ofthe efficacy of treatment of Fabry disease: a review of the literature/. Cardiovasc Hematol Agents Med Chem 4 (4): 289–97, October 2006<br>4. J. E. Groener, B. J. Poorthuis, S. Kuiper, M. T. Helmond, C. E. Hollak, J. M. Aerts. “HPLC for simultaneous quantification of total ceramide,glucosylceramide, and ceramide trihexoside concentrations in plasma.” Clin Chem., Apr;53(4):742-7, 2007. Epub Mar 1 2007<br>5. C. Menge, I. Stamm, M. Wuhrer, R. Geyer, L. H. Wieler, G. Baljer. “Globotriaosylceramide (Gb(3)/CD77) is synthesized and surface expressed bybovine lymphocytes upon activation in vitro.” Vet Immunol Immunopathol., Nov;83(1-2):19-36, 2001</br></br></br></br></br> |
